IORD proposes a Section 8, CSR-supported public-interest pharmaceutical model to ensure affordable access to orphan drugs for millions of Indian patients.
Blog
Dr. Vinod K. Paul, Member, NITI Aayog, calls for manufacturing drugs for selected rare diseases, emphasizing affordability, domestic production, and improved patient access.